NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
NO.202405-11, NCT06475755: Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC |
|
|
| Not yet recruiting | 2 | 178 | RoW | Immunochemotherapy combined with antiangiogenic, Tislelizumab, Anlotinib, Cisplatin, Carboplatin, Paclitaxel, Albumin-bound paclitaxel, Pemetrexed, Immunochemotherapy | Tang-Du Hospital | Non-Small Cell Lung Cancer, Anti Angiogenesis | 06/25 | 12/27 | | |
NCT06040606: Postoperative Complications and Mortality With In-Hospital COVID-19 Omicron Infection After Surgery |
|
|
| Completed | N/A | 119 | RoW | In-Hospital COVID-19 Omicron Infection after surgery | Tang-Du Hospital | Postoperative Complications, Morality | 03/23 | 03/23 | | |
